Pursuing Charlene's Dream

Article

Oncology nursing is more than just a job to Barbara Bittner, RN, OCN.

Barbara Bittner, RN, OCN, is an oncology nurse navigator at AdventHealth in Florida. But to her, nursing is much more than just a career. Bittner cares deeply for all of her patients, and even helped establish Charlene's Dream, a resource center for women with cancer, after her friend and Colleague, Charlene, passed away from the disease.

Recent Videos
Photo of a woman with brown hair and bangs, surrounded by a blue border
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Related Content
Digital rendering of lungs on a dark blue background

First-Line Amivantamab With Lazertinib Boosts OS in EGFR-Mutated NSCLC

Kristi Rosa
April 3rd 2025
Article

The combination of amivantamab and Lazertinib improved long-term survival over osimertinib in patients with EGFR-mutated non-small cell lung cancer.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

White line illustration on a dark blue background of a clipboard that says "FDA" at the top next to a shield with a checkmark on it

Oncology Drugs Approved by the FDA in March 2025

Bridget Hoyt
April 1st 2025
Article

The FDA approved treatments in various gastrointestinal and genitourinary cancers in March.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Image of an ovarian cancer cell

Relacorilant/Nab-Paclitaxel May Increase PFS, OS in Ovarian Cancer

Jax DiEugenio
March 31st 2025
Article

Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.

Line illustration of lungs on a cornflower blue background

Osimertinib Sustains OS Improvement in EGFR-Mutant NSCLC

Roman Fabbricatore
March 31st 2025
Article

Osimertinib monotherapy and combination treatment had safety profiles consistent with previous data on use of the drug in EGFR-mutated NSCLC.